Debiopharm: Hepatitis C trials

The registry lists 10 Hepatitis C studies with Debiopharm as lead sponsor. 0 are open to participants now and 8 have results posted.

Phase 2 4Phase 3 4No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C PatientsCompletedNCT02753699Phase 3Results posted
• Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an OptionCompletedNCT02094443Phase 2Results posted
• Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis CTerminatedNCT01500772Phase 3Results posted
• Alisporivir (Deb025) and Boceprevir Triple Therapies in African American Participants Not Previously Treated for Chronic Hepatitis C Genotype 1TerminatedNCT01446250Phase 3Results posted
• Efficacy and Safety of Alisporivir Triple Therapy in Chronic Hepatitis C Genotype 1 Treatment-naïve ParticipantsCompletedNCT01318694Phase 3Results posted
• Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve ParticipantsCompletedNCT01215643Phase 2Results posted
• Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous TreatmentCompletedNCT01183169Phase 2Results posted
• A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard TreatmentCompletedNCT00537407Phase 2Results posted
• Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve PatientsCompletedNCT01970904Not applicable
• A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 PatientsCompletedNCT00854802Not applicable